Expense and cost recovery system

LifePort Liver Transporter by Organ Recovery Systems Wins Fast Company’s 2023 Innovation by Design Award in the ‘Health’ Category

Retrieved on: 
Tuesday, August 22, 2023

Organ Recovery Systems (ORS) is honored to announce that its LifePort Liver Transporter was selected as the winner in the ‘Health’ category in Fast Company’s Innovation by Design Awards for 2023.

Key Points: 
  • Organ Recovery Systems (ORS) is honored to announce that its LifePort Liver Transporter was selected as the winner in the ‘Health’ category in Fast Company’s Innovation by Design Awards for 2023.
  • The Innovation by Design Award is one of the most sought-after design awards in the industry.
  • LifePort Liver Transporter (LLT) is a proprietary medical device designed to optimize the quality of donated livers for clinical transplantation via precision-controlled hypothermic machine perfusion (HMP).
  • “We are very honored that LifePort Liver Transporter and Organ Recovery Systems have been recognized for this award, and most grateful for the visibility this opportunity brings to organ donation and transplantation,” said David Kravitz, CEO of ORS.

Organ Recovery Systems Wins Gold in 12th Annual Best in Biz Awards

Retrieved on: 
Tuesday, December 13, 2022

Organ Recovery Systems (ORS) has been named a Gold winner in the Executive Team of the Year category for Best in Biz Awards 2022.

Key Points: 
  • Organ Recovery Systems (ORS) has been named a Gold winner in the Executive Team of the Year category for Best in Biz Awards 2022.
  • In giving the award, judges highlighted ORS leaderships unique ability to solve major unaddressed market needs in transplantation.
  • For the Best in Biz Awards official press release, visit: https://www.prweb.com/releases/2022/12/prweb19055748.htm
    Organ Recovery Systems is a global market-leading provider of organ preservation products and services, supporting 320 transplant programs across 43 countries.
  • Organ Recovery Systems proprietary LifePort platform has also been successfully designed to accommodate donor livers to help improve transplant outcomes for end-stage liver disease patients.

Organ Recovery Systems’ LifePort® Liver Transporter Preserves First Livers for Transplant as Part of the PILOT™ Continued Access Study

Retrieved on: 
Thursday, December 1, 2022

Organ Recovery Systems (ORS) is celebrating the first liver transplants using the LifePort Liver Transporter (LLT) with Vasosol at Rutgers Medical School in New Jersey and Northwestern Memorial Hospital in Chicago, Illinois.

Key Points: 
  • Organ Recovery Systems (ORS) is celebrating the first liver transplants using the LifePort Liver Transporter (LLT) with Vasosol at Rutgers Medical School in New Jersey and Northwestern Memorial Hospital in Chicago, Illinois.
  • View the full release here: https://www.businesswire.com/news/home/20221201005023/en/
    LifePort Liver Transporter is working to transform the preservation of donor livers.
  • Organ Recovery Systems is a global market-leading provider of organ preservation products and services, supporting 320 transplant programs across 43 countries.
  • Organ Recovery Systems proprietary LifePort platform has also been successfully designed to accommodate donor livers to help improve transplant outcomes for end-stage liver disease patients.

WideTrial to Support Cost Recovery for Personalized Cancer Vaccine Trial and Expanded Access Program

Retrieved on: 
Wednesday, August 31, 2022

SAN FRANCISCO, Aug. 31, 2022 /PRNewswire/ -- WideTrial, Inc. will provide key regulatory support to a personalized cancer treatment program run by the Jaime Leandro Foundation for Therapeutic Cancer Vaccines (JLF) in association with Washington University School of Medicine in St. Louis.In a basket trial for neoantigen synthetic long peptide vaccines, patients with advanced malignancies will be given a customized mix of neoantigen peptides based on their individual tumor mutation profiles.  Cancer patients who do not meet the trial's eligibility criteria or who are geographically remote from the trial centers may still gain the personalized treatment through an Expanded Access Program (an "EAP").WideTrial will conduct the planning and regulatory filings required for FDA-authorized Cost Recovery for both the research trial and the EAP."The recent draft Guidance on Charging for Investigational Treatment under an IND was a great step by FDA to clarify Cost Recovery rules, but it's still a complicated matter," said Jess Rabourn, CEO of WideTrial.  "Our company was created to make this space easier to navigate, ensuring that non-traditional clinical trials, including Expanded Access Programs, are feasible for more clinics to offer to more patients as a care option."In the United States, all Expanded Access Programs and some research trials are eligible for Cost Recovery. This permits a sponsor to pass through some of its costs to interested parties.  It is intended for cases in which the cost burden on the sponsor would otherwise severely restrict the feasibility or scope of the program."We reached out to WideTrial because of Jess's long-standing leadership in Expanded Access but also for his reputation for helping companies understand and utilize Cost Recovery in their clinical development," said William Hoos, President of JLF.  "It's been a successful partnership so far."WideTrial Inc. is a Silicon Valley based health-tech corporation.  Its mission is to make investigational treatment options accessible to all patients with serious and life-threatening health conditions.  To learn more, visit widetrial.comThe Jaime Leandro Foundation for Therapeutic Cancer Vaccines (JLF) is a 501(c)3 nonprofit organization that organizes the complex process necessary to give patients and doctors access to personalized neoantigen vaccines.Contact:Jess Rabourn, CFAWideTrial, Inc.***@widetrial.comPhoto(s):https://www.prlog.org/12931083Press release distributed by PRLog 

Key Points: 
  • Cancer patients who do not meet the trial's eligibility criteria or who are geographically remote from the trial centers may still gain the personalized treatment through an Expanded Access Program (an "EAP").
  • WideTrial will conduct the planning and regulatory filings required for FDA-authorized Cost Recovery for both the research trial and the EAP.
  • In the United States, all Expanded Access Programs and some research trials are eligible for Cost Recovery.
  • "We reached out to WideTrial because of Jess's long-standing leadership in Expanded Access but also for his reputation for helping companies understand and utilize Cost Recovery in their clinical development," said William Hoos, President of JLF.

Global Electronic Cash Register Market- Post Pandemic Recovery Plan Strategies and Processes | Adoption of ECRs by SMEs to Boost Market Growth | Technavio

Retrieved on: 
Saturday, September 19, 2020
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200918005304/en/
    Technavio has announced its latest market research report titled Global Electronic Cash Register Market 2020-2024 (Graphic: Business Wire)
    The market has been witnessing strong demand for ECRs from SMEs over the recent years.
  • Thus, the increasing adoption of ECRs by SMEs is one of the key factors driving the growth of the global electronic cash register market.
  • This market research report segments the electronic cash register market by end-user (retail and hospitality) and geography (APAC, Europe, North America, South America, and MEA).
  • The APAC region led the electronic cash register market share in 2019, followed by Europe, North America, South America, and MEA respectively.

Global Electronic Cash Register Market 2019-2023 | Evolving Opportunities with CASIO COMPUTER CO., LTD. and Hewlett Packard Enterprise Development LP | Technavio

Retrieved on: 
Saturday, October 12, 2019
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20191011005327/en/
    Technavio has announced its latest market research report titled global electronic cash register market 2019-2023.
  • In addition, the shift toward cloud-based solutions is anticipated to further boost the growth of the global electronic cash register market.
  • Thus, the increasing adoption of ECRs by SMEs is one of the key factors driving the growth of the global electronic cash register market.
  • Major Five Electronic Cash Register Market Companies:
    CASIO COMPUTER CO., LTD. owns and operates the businesses across consumer, system equipment, and other segments.